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1. Introduction 
Cardiovascular involvement in systemic lupus erythematosus (SLE) was first reported by 
Kaposi in 1872 of cardiac irregularity and dyspnea. In 1924, Libman and Sacks reported 
verrucous endocarditis but ironically did not recognize the association of verrucous 
endocarditis with SLE. (Petri, 2004) In the last decade, newly recognized clinical entities 
have been described with the introduction of very sensitive, non-invasive  and semi-
invasive cardiac imaging techniques.(Turiel, 2005) With the use of very sensitive methods of 
cardiovascular investigations, it has been found the prevalence of cardiac involvement to be 
>50%. (Petri, 2004) 
Several autoantibodies such as antiDNA, anti-phospholipid antibodies (apl), antiSSA (Ro 
antibodies) and antiendothelial cell antibodies present in patients with SLE can mediate 
cardiac damage. These autoantibodies can directly affect the heart tissue or, alternatively, 
trigger mechanisms able to cause heart damage for example, apl can contribute to cardiac 
damage enhancing atherosclerosis phenomena, causing thrombosis of coronary arteries or 
starting an immune-complex mediated reaction and deposition at the valve level. 
Consequences of autoantibody damage has been reported in several heart structures such as 
the valves, myocardium, pericardium, conduction tissues and cardiac arteries in patients 
suffering from SLE, antiphospholipid syndrome (APS), Sjogrens syndrome and other 
autoimmune rheumatic diseases(ARD). (Tincani et al, 2006) 
Overall improvements in medical care including the availability of antibiotics, 
antihypertensive, and renal replacement therapy coupled with the judicious use of 
glucocorticoids, antimalarial and immunosuppressive drugs have led to improved survival 
of SLE patients in the past 50 years. (Nikpou, 2005) In 1976, Urowitz first described the 
‘bimodal mortality pattern’ of SLE. This  observation was based on SLE  deaths early in the 
course of the disease were due to active SLE and use of high dose steroids  associated with 
complications such as infection and sepsis. Later in the disease course (›5 years after 
diagnosis) deaths were frequently associated with inactive SLE, long duration of 
prednisolone therapy and myocardial infarction (MI) due to atherosclerotic heart disease. 
(Urowitz, 1976) Cardiac disease has recently been acknowledged as a primary cause of 
morbidity and mortality in SLE as well as APS, and numerous factors leading to accelerated 
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atherosclerosis has been characterized. Though cardiac involvement is a uncommon cause 
of flare: it can be forgotten unless a full blown cardiac dysfunction or complication is 
present. In a prospective study of flares, serositis was present in only 7-9% of the flares. 
(Petri, 1991) With prolongation of life by modern immunosuppressive therapies, heart 
lesions develop in all patients at sometime during the course of their disease. 
The present chapter: 
Emphasizes  and describes the cardiac involvement  in SLE which may involve all  three 
layers of the heart (pericardium, myocardium and the endocardium).Appreciate the early 
identification and management of these conditions prevents the late life threatening 
complications and consequences. Recognize the importance of premature atherosclerosis 
and that it is the major cause for mortality and premature death in lupus patients. 
Understand the causation is multifactorial:  traditional risk factors as well as SLE related risk 
factors and inflammatory mediators are involved in the pathogenesis. Early identification 
and treatment of modifiable risk factors in SLE patients are discussed. There have not yet 
been any published randomized, controlled trials in patients with SLE in respect to CVD 
risk factor modifications. Thus treatment and management recommendations are based on 
published guidelines for other populations at high risk for CVD. 
2. Pericarditis 
2.1 Clinical features 
Pericarditis is the most common cardiac manifestation of active lupus, although often it is 
not evident clinically. Pericarditis can occur at any time during the course of SLE, it tends to 
be one of the earlier cardiac manifestations, and can even be the first manifestation of 
lupus.( Brigden, 1960) Pericarditis was the presenting sign of lupus in 4 of  28  patients who 
ultimately developed it in one series.(Godeau et al.1981)  Pericarditis in SLE presents  in the 
typical way, with precordial pain, usually positional (aggravated by lying down), often with 
a pleuritic quality, and sometimes with dyspnea. Coexistent pleurisy and/or effusions are 
common, occurring in 14 of 28 cases in same series. (Godeau et al., 1981) Pericarditis usually 
appears as an isolated attack or as recurrent episodes, with or without symptoms. Patients 
may have fever and tachycardia. Friction rubs are rare, perhaps because they are present 
often for only a few hours and are missed. The “classic” pericardial friction rub has three 
components, occurring with ventricular contraction, atrial contraction, and at the end of 
rapid ventricular filling.( Petri, 2004) In a French series, of 28 cases of pericarditis, 23 had 
pain, 12 had a rub, and 4 required pericardiocentesis because of tamponade.(Godeau et 
al.,1981) Patients with pericardial effusion (as opposed to thickening) are more likely to have 
pericardial pain and active lupus elsewhere.( Leung et al, 1990,Cervera et al, 1992 ) In the 
study by Cervera et al, only the patients with moderate or severe pericardial effusion had 
clinical or electrocardiographic evidence of pericarditis.( Cervera et al, 1992 ) When present, 
pericardial effusions are usually small and do not cause hemodynamic problems. Pericardial 
tamponade is rare and has been reported as an initial presentation (Topaloglu, 2006) and 
even in treated patients. (Shearn, 1959 In a series reported by Rosenbaum, 9 of the 71 
patients with pericardial effusion developed pericardial tamponade( 21%) of which 5 of the 
9 patients required a pericardial  window.(Rosenbaum, 2009) Constrictive pericarditis is 
very rare. Only four cases of constrictive pericarditis have been reported. In two of the four 
cases constrictive pericarditis developed in spite of corticosteroid therapy. All four known 
cases have occurred in males. (Petri, 2004) 
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Fig. 1. Serositis in a 13-year-old boy with SLE. Contrast-enhanced CT scan shows bilateral 
pleural effusions (*), cardiomegaly, and a pericardial effusion (arrow). Bilateral lower lobe 
atelectasis is also present. (Lalani & Hatieldl, 2004) Copyright permission from RSNA 
2.2 Diagnosis 
If a patient presents for the first time with pericarditis, it is usually impossible to invoke SLE 
as the cause until appropriate laboratory tests are available suggesting the diagnosis. 
However, patients with idiopathic pericarditis more often give a history of recent viral 
infection, and are more often male. In idiopathic pericarditis there is usually a leukocytosis, 
whereas a finding of leucopenia would suggest SLE. Pericardial friction rubs may be heard 
in sicker and untreated patients, but are often absent in milder cases, especially those 
patients already on corticosteroid and/or NSAID treatment. A significant rise in jugular 
venous pressure is unusual. (Petri, 2004) In one series, most patients showed 
electrocardiographic evidence of acute or chronic pericarditis. (Brigden et al, 1960) The 
diagnosis of pericarditis can be confirmed by ECG findings of elevated ST segments and tall 
T waves (although slight T-wave changes or transient elevation of ST segments are most 
characteristic), or by cardiac echocardiogram findings of pericardial effusion or thickened 
pericardium. Serial electrocardiograms may show a progression of changes in pericarditis. 
Initially, a diffuse elevation of ST segments (without reciprocal ST segment depression) is 
found. This is followed by a lowering of ST segments back toward baseline and subsequent 
T-wave inversion. In most cases, T waves then return to normal. (Petri, 2004) Effusions may 
be accompanied by a drop in voltage. After severe attacks, the T waves may not recover to 
their original voltage.(Brigden, 1960) In the series of Godeau et al., of 28  cases, 5 had low 
voltage, 10  had ST changes, and 20 had depolarization changes.(Godeau et al, 1981) Both 
effusion and thickening are frequent in echocardiogram studies. Most effusions are mild. 
Echocardiography (two-dimensional echocardiogram and Doppler echocardiography) is the 
modality of choice in evaluating pericardial disease, because it is both noninvasive and 
sensitive. However, echocardiography may be an insensitive technique in diagnosing 
pericarditis when it is not accompanied by effusion or thickening. (Petri, 2004)  
2.3 Prevalence 
The frequency of pericarditis depends on the modality of diagnosis.Published series  
of patients find pericarditis in 12–47% of living SLE patients.(Petri, 2004) In general, the  
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Fig. 2. Lupus pericarditis in a 42-year-old woman. Contrast-enhanced CT scan demonstrates 
cardiomegaly, a thickened and enhancing pericardium, and a pericardial effusion. . (Lalani 
& Hatieldl, 2004) Copyright permission from RSNA 
echocardiogram is more sensitive than clinical diagnosis, with 19–54% of patients having 
pericardial effusion or thickening. The echocardiogram is an essential tool in the clinical 
management of sick patients with cardiac lupus, because clinical diagnosis alone may be 
faulty. Pericardial abnormalities are the most common echocardiographic finding in SLE 
patients.(Leung, 1990) However, significant pericardial disease is uncommon, even using 
echocardiograms, being found in only 7% in one study by Cervera et al. (Cervera et al , 1992) 
Autopsy studies find a much higher prevalence of pericardial involvement, ranging up to 
61–100%. (Petri, 2004)                        
2.4 Pathology 
Pericardial fluid in SLE is usually exudative, the amount of fluid varying from 100 to more 
than 1000 cc.(Tincani, 2006)White blood counts are in the 30,000 range, primarily 
neutrophils. Although not helpful in patient management, the fluid may contain anti-DNA 
and have low complement levels. Complement-fixing material was found in pericardial 
fluid in patients with SLE, which was felt to be immune complexes. (Petri, 2004)  At autopsy, 
a diffuse or focal fibrinous pericarditis, often with many hematoxylin bodies, with or 
without effusion, was found. In the series of Brigden et al., the layers of the pericardium 
were obliterated with occasional deposits of fresh fibrin or effusion. (Brigden, 1960) In 
another autopsy study, of 11 cases, 6 had acute pericarditis and 5 had chronic obliterative 
pericarditis (2 of these had pericardiomediastinal adhesions). (Bidani, 1980) 
 The histopathology in a case of constrictive pericarditis showed fibrosis and mild chronic 
inflammation, with IgG, IgM, and complement deposition on immunofluorescence. 
Immunopathogenetic analyses of the pericardium in 2 of 9 patients in an autopsy series 
demonstrated the vascular deposition of immunoglobulin and complement. (Bidani, 1980) 
On histopathology, small pericardial blood vessels were surrounded by an infiltrate of 
lymphocytes, plasma cells, macrophages, and rare polymorphonuclear leukocytes. On 
immunofluorescence, IgG was present in a predominantly granular pattern around small 
pericardial vessels.Thus, Bidani and colleagues concluded that immune complex deposition 
was the cause of pericarditis. (Bidani, 1980) 
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2.5 Treatment 
In early studies, pericarditis usually responded quickly to corticosteroids, with serial chest 
x-rays showing rapid and radiologic evidence of resorption of fluid.(Brigden,1960) Shearn 
commented in his review that the “often transient nature of pericarditis makes evaluation of 
therapy for this condition most difficult.(Shearn, 1959) However, many studies have noted 
pericardial effusion developing or persisting even with corticosteroid treatment, such as the 
autopsy study of Kong et al., in which 11 of 12 patients with pericardial effusion had taken 
corticosteroids.(Kong et al,1962) Occasionally patients progressed to the point of 
tamponade.(Rosenbaum, 2009) Nonsteroidal anti-inflammatory drugs are helpful for mild 
cases of pericarditis. Patients presenting with pericardial tamponade may necessitate 
pericardiocentesis. Refractory cases of large pericardial effusions may benefit from a 
pericardial window. (Rosenbaum, 2009) 
3. Myocarditis 
3.1 Clinical features 
Myocarditis, as recognized clinically, is rare in SLE. The clinical detection of myocarditis 
ranges from 3 to 15%, although it appears to be much more common in autopsy studies 
suggesting the largely subclinical nature of the myocardial pathology. Patients may present 
in florid congestive heart failure, or more subacutely with tachycardia and dyspnea. 
Myocardial abnormalities were found in 20% of patients using echocardiograms, but only 
one patient with an echocardiographic pattern of myocarditis developed myocardial 
dysfunction clinically.(Cervera, 1992) 
Even autopsy studies have shown that myocarditis usually does not lead to cardiac 
dilatation.(Griffith & Vural, 1951) Brigden et al. had no patient in whom congestive heart 
failure was attributed solely to myocarditis.(Brigden et al, 1960)  Shearn had only one 
patient with heart failure attributable to myocarditis.(Shearn,1959) 
However, other series have found myocarditis as a cause of congestive heart failure. (Petri, 
2004) Harvey et al found that myocarditis was the cause of heart failure in 8 of their 9 
patients. (Petri, 2004)  Hejtmancik et al. found myocarditis to be the major cause in 6 of their 
10 cases. (Hejtmancik et al, 1964). Kong et al. had 17 patients with cardiomegaly; at autopsy, 
15 had myocarditis but of varying degrees of severity.(Kong et al,1962) 
The differential diagnosis of congestive heart failure in SLE would include lupus 
myocarditis, viral myocarditis, toxic myocarditis due to use of antimalarial drugs, anemia, 
renal failure, pulmonary disease, atherosclerotic heart disease, coronary arteritis, valvular 
disease, and hypertension. 
3.2 Diagnosis 
The clinical recognition of myocarditis can easily be missed. In most cases, the patient who 
had a hematologic and renal flare was not recognized to have myocarditis as well until they 
presented in congestive heart failure. Myocarditis should be considered in patients with 
tachycardia not due to fever, in patients with a third heart sound (S3), in patients with 
abnormal ECGs, in those with new murmurs or conduction disturbances, and in those with 
congestive heart failure. (Shearn, 1959) Brigden et al. suggested that prolongation of the 
conduction time of either P–R, QRS, or Q–T interval would have been evidence of 
myocarditis (in the absence of another cause of ventricular hypertrophy), but that they did 
not encounter these ECG changes in their series.(Brigden, 1960) 
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Hejtmancik et al. made a clinical diagnosis of myocarditis in 21% of their patients (after first 
excluding hypertension and coronary artery disease), based on (1) cardiac enlargement, (2) 
ventricular gallop, and (3) electrocardiographic abnormalities.(Hejtmancik et al, 1964) Kong 
et al. found myocarditis at autopsy in 15 of their 16 patients with gallop rhythm.(Kong et al, 
1962).The diagnosis of myocarditis can be supported by the finding of global hypokinesia on 
cardiac echocardiogram and may be confirmed by right ventricular endomyocardial 
biopsy.(Petri,2004) Although echocardiography cannot diagnose myocarditis with certainty, 
global hypokinesia, in the absence of other known causes, is strongly suggestive.(Busteed et 
al, 2004) Other investigations that may help to diagnose myocarditis include a gallium 
scan18 and magnetic resonance imaging (MRI).(Saremi et al, 2007) Nuclear medicine scans 
rely on labeling of anti myosin antibodies with radiopharmaceuticals, and may not be 
available in all clinical settings. Different MRI techniques may support the diagnosis of 
myocarditis. Contrast enhancement of the myocardium in the setting of acute myocyte 
membrane rupture results in greater passive diffusion of contrast into the affected 
intracellular space. A midwall myocardial hyperenhancement pattern is the most frequent 
finding in both acute and chronic myocarditits, while a subepicardial distribution of lesions 
is reported only in patients with acute myocarditis.(Saremi et al,2007) However, it is 
important to note that MRI alone cannot differentiate viral myocarditis from other causes of 
acute dilated cardiomyopathy. A biopsy is not required in many cases of lupus myocarditis, 
as the sensitivity and specificity are unknown; but can be useful in some patients to confirm 
the clinical diagnosis, determine the severity of myocardial involvement, and distinguish 
this disorder from other causes of myocardial disease  like drug induced etc.(Wijetunga & 
Rockson, 2002) New-onset heart failure of less than 6 days’ duration associated with 
hemodynamic compromise is an American Heart Association/American College of 
Cardiology/European Society of Cardiology class I indication for endomyocardial 
biopsy.(Cooper et al,2007) 
3.3 Prevalence 
In large series of patients, the clinical diagnosis of myocarditis has been made in up to21 %. 
(Petri, 2004) Autopsy studies, mainly done in the 1950s and 1960s, frequently found 
myocarditis. More recent postmortem studies,(Bindani, 1980) reflecting the era of 
corticosteroid treatment, found much lower frequencies, from 0 to 8%. Echocardiographic 
studies cannot definitively diagnose myocarditis, but global hypokinesia, in the absence of 
other known causes, is strongly suggestive. (Appenzeller, 2011) Large echo series have 
found frequencies of global hypokinesis between 5 and 20%. However, segmental areas of 
hyopkinesis on echocardiogram can also be indicative of myocarditis. Newer imaging 
modalities, such as magnetic resonance, are largely unstudied. (Appenzeller, 2011) 
3.4 Pathology 
A common misperception is that myocarditis in SLE is a myositis. CPK levels are usually 
normal.(Petri, 2004) In fact, only one study found any association with myositis 
elsewhere.(Borenstein et al, 1978)  Myocarditis in SLE is a complicated process, with arteritis 
or arteriopathy, not primary disease of the myocardial fibers, playing a major role. Kong et 
al. found pathologic evidence of myocarditis (fibrinoid and collagenous degeneration, 
interstitial edema, necrosis, and/or cellular infiltration) in 15 of 30 autopsies. (Konget al, 
1962) The cellular infiltrates of myocarditis consist of foci of interstitial plasma cells and 
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lymphocytes. Immunofluorescence studies confirm that the etiopathogenesis is vascular. In 
one study, most of the immune deposits were present in the walls of blood vessels of the 
myocardium.(Bidani, 1980) Immunofluorescence studies of endomyocardial biopsies reveal 
perivascular deposits of IgG and vascular deposits of C3.(Appenzeller, 2011)  A rare and 
aggressive form is giant cell myocarditis, which is associated with extensive myocytes 
necrosis, a mixed dense lymphoplasmacytic infiltration, numerous multinucleated giant 
cells and degranulatd esinophils, leads to rapidly developing progressive congestive heart 
failure and arrhythmias.(Chung et al, 2005; Martorell et al, 2008) Antimalarial-related 
myocarditis is often associated with skeletal muscle involvement showing curvilinear and 
myeloid bodies.(Nord et al,2004) 
3.5 Treatment 
Myocarditis that comes to clinical attention is usually an urgent situation. Treatment with 
high-dose intravenous methylprednisolone (such as the “pulse”regimen, 1000 mg daily for 3 
days), followed by high dose IV or oral corticosteroid maintenance therapy, is indicated. 
Intravenous “pulse” cyclophosphamide is added in refractory cases and patients with heart 
failure. Initial six cycle of monthly pulses of cyclophosphamide 750mg/m2, followed by a 
repeated cycle if LVEF has not completely normalized, is relatively well tolerated and 
effective. (Van der Laan Baalbergen et al, 2009) Intravenous immunoglobulin's have been 
used in one or two case reports with some success.(Sherer et al, 1999) 
Supportive therapy for congestive heart failure, including diuresis, digoxin, and afterload 
reduction (such as with angiotensin converting enzyme (ACE) inhibitors) may be necessary. 
Anticoagulation should be considered in those patients who have progressed to the stage of 
cardiomyopathy. Efficacy of therapy can be assessed by serial echocardiographic studies.  
One potential therapeutic option in advanced stages of heart failure regardless of the source 
is cardiac resynchronization therapy (CRT). There have been several reports illustrating the 
successful use of cardiac resynchronization in patients with SLE and resistant 
cardiomyopathy. (Reza et al, 2011) Mortality is higher in giant cell myocarditis than other 
forms of myocarditis. (Cooper et al, 1997)Cardiac transplantation is an option in refractory 
cases. (Reza et al, 2011)    
4. Valvular disease 
4.1 Clinical features 
Verrucous endocarditis can affect valve leaflets, papillary muscles, and the mural 
endocardium, as initially described by Libman and Sacks. However, Libman and Sacks and 
Gross  found the tricuspid valve involved most often, whereas more recent studies have 
found the mitral valve (followed by aortic) to be most affected.(Petri, 2004) In the 
corticosteroid era, valvular vegetations are found less frequently. Shearn found that none of 
11 patients who received corticosteroids had verrucous endocarditis, but 4 patients, who 
died before corticosteroid therapy was available, did. (Shaern, 1959) In their landmark 
autopsy study, Bulkley and Roberts also commented on the rarity of vegetations in 
corticosteroid treated patients. (Bulkley & Roberts, 1975) Occasionally, the presentation may 
be fulminant, with congestive heart failure due to mitral regurgitation, or brain emboli 
secondary to valvular vegetations. Verrucous endocarditis (vegetations, “Libman- Sacks”) 
affects the mitral valve most frequently, followed by the aortic valve. (Petri, 2004) 
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Fig. 3. Libman Sacks Endocarditis.  
The presence of vegetations predisposes patients to bacterial endocarditis.(Brigden et 
al,1960) Although verrucous endocarditis can produce both systolic and diastolic murmurs, 
these are rarely of sufficient hemodynamic importance to cause congestive heart failure. 
There is virtually no correlation between the presence of verrucous endocarditis and cardiac 
murmurs. Shearn found that systolic murmurs occurred in 70% of SLE patients. (Shearn, 
1959) Most murmurs were low intensity, and were heard loudest (47%) at the apex. Because 
murmurs were also associated with fever, infection, tachycardia, and anemia, the 
differential diagnosis of a new murmur was complex.  
Diastolic murmurs occur in only 4% of SLE patients. (Petri, 2004) The differential diagnosis 
of diastolic murmurs in SLE includes rheumatic or congenital heart disease, bacterial 
endocarditis, Libman-Sacks endocarditis, and left ventricular dilatation. In general, even 
when the valvular vegetations of Libman-Sacks endocarditis are large, they do not involve 
the line of closure, and therefore should not deform the valve. Even involvement of the 
chordae tendineae should not be sufficient to distort the valve. There are several 
documented cases, however, in which Libman-Sacks endocarditis appeared to be the only 
explanation for a diastolic murmur. (Petri, 2004) Two of the four patients with Libman-Sacks 
endocarditis in Shear's series had a diastolic murmur suggestive of mitral stenosis. 
However, diastolic murmurs were also heard in two patients without Libman-Sacks 
endocarditis. (Shearn,1959) It is rare for valvular disease in SLE to be clinically significant. In 
a series of 421 patients, only 1 to 2% had significant morbidity or mortality. Of the 14 cases 
with available pathology, only 6 had evidence of SLE valvulopathy, either verrucous 
vegetations or valvulitis with necrosis and vasculitis. (Straaton et al, 1988) 
4.2 Diagnosis 
Transesophageal echocardiogram is the modality of choice in terms of sensitivity in 
detecting valvular disease due to either lupus or anti-phospholipid antibody syndrome. 
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(Petri, 2004) Most previous series used M-mode echocardiography or two-dimensional 
Doppler echocardiography and are not completely comparable. Patients with new murmurs 
or with valvular abnormalities on echocardiogram should have blood cultures to rule out 
bacterial endocarditis. 
4.3 Prevalence 
The prevalence of valvular disease in SLE is very high by echocardiography accounting for 
54% of the patients.(Maksimowicz-McKinnon & Mandell, 2004) Valvular disease, for the 
most part, however, is mild and asymptomatic. 
4.4 Pathology 
Valvular disease occurs predominantly as vegetations (what was termed Libman-Sacks 
endocarditis in the past), or thickening (that can present as either a regurgitant or stenotic 
lesion). The mitral valve is affected most often, followed by the aortic valve. Mitral and 
aortic regurgitation are the most common findings, with stenotic lesions being very rare. 
Aortic cup sclerosis has been identified as common lesion.The typical valvular and mural 
endocarditis lesions, which are verrucous, occur as single vegetation or as mulberry-like 
clusters. When occurring on valves, the vegetations are often on the ventricular surface, 
near, but not distorting, the line of closure. (Shapiro et al, 1977) The original histologic 
description of Libman-Sacks endocarditis emphasized the multiplication of endothelial cells, 
proliferation of Anitschow myocytes, and infiltration of mononuclear cells in the valve ring 
and valve base, especially the valve pocket. Aggregations of hemosiderin were frequent, 
along with some fibrosis. Cells underwent karyolysis to form hematoxylin bodies. The 
mural endothelium was affected, especially near the mitral valve. (Brigden et al, 1960) 
Histologic studies showed three distinct zones, an outer exudative layer of fibrin, nuclear 
debris, and hematoxylin-stained bodies; a middle organizing layer of proliferation of 
capillaries and fibroblasts, and an inner layer of neovascularization. Immunofluorescence 
showed immunoglobulin and complement deposition in the walls of small junctional 
vessels in the inner zone of neovascularization, suggesting that circulating immune 
complexes were critical in the development of the vegetations.(Shapiro et al, 1977) Bidani et 
al. found immunoglobulins and complement deposition in the valve stroma and vegetations 
in one patient with Libman-Sacks endocarditis. (Bidani, 1980) It is not clear whether 
Libman-Sacks endocarditis evolves into the valvular thickening that is the second important 
form of SLE valvulopathy. In modern series, valvular thickening is found more commonly 
than vegetations (Leung, 1990). Galve et al. found that patients with Libman-Sacks 
endocarditis were younger, had shorter disease duration, and had received less 
corticosteroid therapy than those with thickened valves. (Galve et al, 1988)  The patients 
with valvular thickening were more likely to have stenotic or regurgitant lesions and to 
require valve replacement. (Galve et al, 1988)  Some authors have expressed concern that 
corticosteroid treatment might increase the chance that a valve would develop thickening. 
Changes in valve thickening can occur over time, with valve thickening resolving or  
new valve thickening appearing. Studies are conflicting on the role of antiphospholipid 
antibodies playing in the development of the vegetations of Libman-Sacks endocarditis. 
Valvulopathy is common in the primary anti-phospholipid antibody syndrome,  
usually found in about a third of patients in large series. (Khamashta et al, 1990) Thrombus 
formation, usually on the mitral valve, can be massive and require valve replacement.  
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Mitral and/or aortic valve thrombus (or vegetations) can also be a precipitant of embolic 
strokes. In SLE patients, some series have shown significantly more valvulopathy in those 
with anticardiolipin antibody.(Khamashta et al,1990) In patients with the secondary form of 
anti-phospholipid antibody syndrome and valvulopathy, there is deposition of 
immunoglobulin and complement, but in addition there is binding of anticardiolipin 
antibody.(Petri, 2004) 
4.5 Treatment 
Systemic lupus erythematosus patients with large, sterile vegetations should be 
anticoagulated to lessen embolic complications. High-dose corticosteroids for 4 to 6 weeks 
are used to shrunken the vegetations, but this approach is controversial.( Nesher et al, 1997) 
Some studies have suggested that corticosteroid treatment may contribute to ultimate valve 
thickening, but this is unproven. In the presence of significant regurgitation, even in the 
absence of nodules, there is a high risk of bacterial endocarditis particularly in the setting of 
jet lesions and warrant antibiotic prophylaxis. (Roman & Salmon, 2007) 
5. Arrhythmia and conduction defects 
5.1 Clinical features 
Many autoimmune diseases including systemic lupus erythematosus have a high incidence 
of autonomic nervous system dysfunction, especially those of cardiac origin. Conduction 
disturbances and arrhythmias occur in about 10% of patients with SLE. (Mandell, 1987)  
Conduction defects include AV block, BBB and complete heart block, which is rarely seen in 
adults. While the most common arrhythmic manifestation include sinus tachycardia, atrial 
fibrillation, atrial ectopic beat and rarely ventricular arrhythmias. (Eisen et al, 2009) 
Recently, other anti-SSA/Ro-associated cardiac manifestations have been described in 
children born to anti-SSA/Ro positive mothers. These include transient fetal first-degree 
heart block, QTc prolongation, sinus bradycardia, late onset cardiomyopathy, endocardial 
fibroelastosis and cardiac malformations. Anti-SSA/Ro antibodies are usually not 
pathogenic to the adult heart, but recently QTc prolongation has been reported in adult 
lupus patients as well.(Costedoat-Chalumeau et al, 2005) 
Sinus tachycardia is the most common cardiac abnormality seen among SLE patients. It is 
present in about 50% of cases (Hejmancik et al, 1964) and it could be the only manifestation, 
also it can be correlated to the disease activity. (Guzman et al, 1994) Arrhythmia and 
conduction defects in SLE patients may be found incidentally or during disease flare, and 
usually develop with coexisting cardiac manifestation (such as pericarditis, myocarditis and 
coronary heart disease though, arrhythmia may be the first manifestation of SLE . (Cardoso 
et al, 2000)Patients with SLE may have prolonged Q-T interval, and this can be a predictor of 
cardiovascular morbidity and mortality. (Okin et al, 2000) 
5.2 Pathogenesis 
SLE can lead to arrhythmias and conduction disturbances either as a consequence of 
pericarditis and myocarditis through direct injury of the conduction system of the heart by 
inflammatory processes.(Eisen et al, 2009)Supraventricular arrhythmias are usually transient 
and recedes as soon as the disease is controlled and treated.(Mandell, 1987) They can also be 
due to myocardial fibrosis as a consequence of occlusive diseases, ( ischemia ) due to 
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vasculitis and atherosclerosis involvement (Eisen, 2009).These mechanisms will result in 
collage deposits that accumulate within nodes , causing fibrosis and focal degeneration of 
the conduction system.(Barati et al, 1975) Autopsy studies have found arteritis of the sinus 
node, vascular occlusion, vasculopathy, and fibroblastic replacement of the sinuatrial and 
atrioventricular nodes.(Barati et al, 1975) Q-T interval prolongation is hypothesized to be 
due to the subclinical atherosclerosis that is known to be augmented in SLE patients , and 
thus , it can be a marker of silent undetected atherosclerotic vascular disease in SLE 
patients.(Cardoso et al, 2005) In addition to Q-T interval prolongation, refractory ventricular 
arrhythmias could be associated with chronic hydroxychloroquine therapy for SLE. (Chen et 
al, 2006)  
5.3 Management  
Diagnosis of arrhythmia and conduction defects is by electrocardiograms that are performed 
usually in patients with an active disease during hospitalization. Those who have had 
arrhythmias or conduction abnormalities need continuous ECG monitoring. (Petri, 2004) 
The life threatening conduction defects are treated with permanent pacemaker, while the 
supra ventricular arrhythmias (unexplained sinus tachycardia) can be controlled with 
corticosteroids. (Costedoat-Chalumeau, 2005; Guzman et al, 1994)       
6. SLE hypertension 
6.1 Prevalence 
Hypertension has a high prevalence among SLE patients ranging from ( 35 to 74% ) 
according to different studies (Doria et al, 2003; Petri, 2000) and it is considered as a major 
risk factor for the progression of  renal , vascular and cardiovascular diseases.  In addition, 
it’s a major risk factor of severe ischemic stroke, thus reflect the need of regular assessment 
and strict blood pressure control among SLE patients. (Mikdashi, 2007)  
6.2 Pathophysiology    
The pathogenesis of hypertension in SLE is multifactorial where alteration of renal function 
plays a central role; other mechanisms can contribute such as renin angiotensin aldosterone 
system (RAS), endothelin, oxidative stress, sex steroids and metabolic changes. Involvement of 
the kidneys in the course of SLE is common and impaired renal function plays a role in 
development of hypertension by alteration in the renal hemodynamic that leads to reduction 
in glomerular filtration rate (GFR) and increase in BUN and plasma creatinine levels. (Nakaro 
et al, 1998)  Renal tubular lesions are prevalent in SLE patients, (Daniel et al, 2001) as well as 
glomerular injury in the form of glomerulonephritis contributes to SLE hypertension that is 
clinically indicated by the presence of urinary protein in SLE patients. (Ryan, 2009) SLE is 
usually associated with impaired endothelial function as demonstrated by the high risk of 
atherosclerosis, and this may also have a role in development of SLE hypertension. (Ryan, 
2009)The Renin Angiotensin Aldosterone System (RAS) is activated in SLE (Herlitz et al, 1984) 
on basis of effectiveness of BP control with ACE Inhibitors and evidence of increase renin, 
which thus can play a role in developing SLE hypertension. (Ryan, 2009) 
Endothelin 1(ET-1) plays a role in the pathophysiology of hypertension through its potent 
renal vasoconstriction and its ability to cause water and sodium retention.(Miyauchi & 
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Masaki, 1999) Evidence suggests that ET-1 could have role in the progression of SLE and SLE  
hypertension as the level of ET-1 are found to be increased in SLE.(Julkunen et al, 1991) 
Activated RAS and increased ET 1 levels in SLE could lead to the generation of oxidative stress 
(Ryan, 2007) that is suggested to be important in pathogenesis of SLE( Alves & Grima, 2003)  
and it is recognized as a promoter of hypertension through mechanisms such as vascular 
dysfunction , renal injury and increase sodium reabsorption.(Manning et al, 2003) In addition , 
metabolic factors can contribute in the pathophysiology of hypertension in SLE and these 
include: Leptin, which is found to be increased, insulin resistance, and obesity.(Gehi et al 2003)  
Inflammatory cytokines (IL-6, TNF┙, and CRP) correlate in the mechanism of hypertension. 
(Bastista, et al, 2005)As these cytokines are increased in SLE, they are suggested to be 
involved in SLE hypertension through mechanisms such as, promotion of renal vascular 
endothelial dysfunction, generation of oxidative stress and progression of insulin resistance. 
(Garcia-Gonzalez et al, 2002) 
6.3 Management  
(Discussed in the section of management of traditional risk factors 8.6.1.) 
7. Coronary arteritis 
7.1 Clinical features 
Coronary arteritis is extremely rare in SLE. In some cases, it has been found at autopsy, with 
no clinical correlate during life. The most common clinical presentation is angina and/or 
myocardial infarction, in a child or young adult who does not have a long history of 
corticosteroid therapy. (Petri, 2004) There is no clear correlation with extracardiac disease 
activity, although it has been present in some case. (Korkmaz & Cansu, 2007) Three of eight 
SLE patients who had a coronary artery aneurysm had no physical or laboratory evidence of 
active SLE. (Wilson et al, 1992) Aortic aneurysms can also occur in SLE. (Ohara et al, 2000) 
7.2 Diagnosis 
It is often difficult to distinguish coronary arteritis from accelerated atherosclerosis. Serial 
coronary angiography has been proposed as the most useful diagnostic modality. Arteritis is 
suggested when coronary aneurysms are found, if there are smooth focal lesions, or if there 
are rapidly developing stenoses.(Petri, 2004) However, Wilson et al. described a patient with 
rapidly progressive coronary artery occlusions in whom only advanced atherosclerosis was 
found at autopsy. (Wilson et al, 1992) Thrombosis or spasm can further confuse the 
interpretation of coronary angiograms. (Korkmaz & Consu, 2007) 
7.3 Prevalence 
There are few studies that allow any estimate of the prevalence of coronary arteritis. (Petri, 
2004) In one study in the 1960s, 6 of 16 patients were found to have arteritis at autopsy. 
(Hejmancik et al, 1964) 
The cases identified have a predilection for pediatric patients or very young adults, with 
rare exceptions. Unfortunately, where follow is given, the outcome is usually death. 
7.4 Pathology 
Histopathology demonstrates transmural vasculitis with both lymphocytic and neutrophilic 
infiltration of a thrombus. (Korkmaz & Consu, 2007)Immunofluorescence studies 
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demonstrate immunoglobulin and complement deposition in coronary arteritis. (Korbet et 
al, 1984) 
7.5 Treatment 
The differentiation of coronary arteritis from atherosclerosis is essential for appropriate 
management. Coronary artery bypasses surgery, angioplasty, or stent placement would be 
considered in patients with severe atherosclerotic disease, but would be contraindicated in 
patients with coronary arteritis. Case reports suggest that corticosteroid therapy can have 
rapid benefit in patients with coronary arteritis. Corticosteroid therapy resulted in relief of 
angina and angiographic improvement. (Kozkmaz & Cansu, 2007)  Not all patients with 
coronary arteritis do well on corticosteroids, however Heibel et al. describe a patient with 
coronary arteritis who was treated with prednisone and cyclophosphamide, but had new 
myocardial damage after starting therapy. (Heibel et al, 1976) Angina did not resolve for 3 
weeks. (Heibel et al, 1976) 
8. Premature atherosclerosis and systemic lupus erythematosus 
8.1 Background-premature atherosclerosis and systemic lupus erythematosus 
Despite improved life expectancy, patients with systemic lupus erythematosus (SLE) are still 
at considerable risk for premature death.(Galdman & Urowitz, 2002) This has been related 
to the high frequency of vascular events (VE) in young to middle-aged SLE patients, in 
whom atherosclerosis develops at an accelerated pace. (Bruce et al, 2003) Although general, 
modifiable risk factors for atherosclerosis are also relevant in SLE, they cannot fully explain 
the increased rate of atheroma formation. (Esdaile et al, 2001) SLE is the prototype of the 
immune complex mediated systemic inflammatory disorders, and inflammation has a 
central place in the pathogenesis and growth of atherosclerotic plaques. (Thomas et al, 2002; 
Becker & Nossent, 2009) Reducing the level of inflammatory activity in SLE would, thus, be 
a rational way to decrease this VE risk. (Pans-Estel et al, 2009) 
Premature atherosclerosis (ATH) has been recognized as a major comorbid condition in 
systemic lupus erythematosus (SLE). Women with SLE in the 35–44year old age group have 
an estimated 50-fold increased risk of myocardial infarction (MI) compared to age and sex-
matched controls. (Manzi, 1997)  Women with SLE  also have an increased incidence of 
subclinical atherosclerosis; in a study using carotid ultrasounds, a 37.1% prevalence of 
carotid atherosclerosis was found in lupus patients compared to 15.2% of 
controls.(Szeknanecz & Shoenfeld, 2006) Although traditional risk factors as defined by the 
Framingham studies (hypertension, hypercholesterolemia, diabetes mellitus, older age, and 
postmenopausal status) are important in increasing risk for ATH in SLE, they do not 
adequately explain the increase in cardiovascular disease. In a Canadian cohort, after 
controlling traditional risk factors, the relative risk attributed to SLE for myocardial 
infarction (MI) was 10.1 and for stroke 7.9 (Esdaile et al, 2001) It has increasingly become 
evident that inflammation and immune mechanisms play an important role in the 
pathogenesis of atherosclerosis in SLE. For many years, the development of atherosclerosis 
in the general population was regarded as a passive accumulation of lipids in the vessel 
wall. Recently, however, it has been realized that inflammation plays a role not only in the 
development of the atherosclerotic lesion but also in the acute rupture of plaques that occurs 
during acute myocardial ischemic events. (Von Felt, 2008) 
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Fig. 4. The bimodal pattern of mortality in SLE patients. (Urowitz et al, 1976; Rubin et al, 
1985) Copyright permission from Elsevier 
8.2 Etiology of premature CVD in SLE 
The pathogenesis of premature atherosclerosis in lupus is multifactorial and includes 
traditional CV risk factors, lupus –related factors and inflammatory risk factors.  Box 1 
8.2.1 The role of inflammation in the pathogenesis of atherosclerosis 
The recruitment of inflammatory cells to the arterial wall Atherosclerotic lesions begin with 
the recruitment of inflammatory cells such as monocytes and T cells to the endothelial wall. 
First, the vascular endothelial cells are stimulated to express leukocyte adhesion molecules, 
including E-selectin, vascular cell adhesion molecule-1(VCAM-1), and intercellular adhesion 
molecule-1 (ICAM-1). (Hansson, 2001)These cell-surface proteins are upregulated during 
periods of inflammation. The expression of adhesion molecules can be induced by 
proinflammatory cytokines such as tumor necrosis factor-a (TNF-a) and interleukin-1 (IL-1), 
which upregulate leukocyte adhesion molecules. (Hansson, 2001) VCAM-1 is also induced 
when endothelial cells are exposed to other inflammatory signals, such as the 
lipopolysaccharides of Gram-negative bacteria, lysophosphatidylcholine (LPC), and 
oxidized phospholipids such as oxidized low density lipoprotein (OxLDL). High-density 
lipoproteins (HDLs) inhibit the expression of adhesion molecules. (Calabresi et al, 1997) 
After leukocytes adhere to the cell surface, they migrate through the endothelium and into 
the intima. (Hansson, 2001) This transmigration is influenced by several factors: first, several 
chemotactic proteins such as monocyte chemotactic protein-1 (MCP-1) are produced by the 
endothelial and smooth cell layers. The expression of MCP-1 in smooth muscle cells and 
endothelial cells can be upregulated by cytokines such as TNF-a, IL-1 and by OxLDL. 
(Hansson, 2001) Conversely, normal HDLs inhibit the expression of MCP-1. The importance 
of MCP-1 in the development of the atherosclerotic plaque is emphasized by the fact that 
elevated circulating levels of MCP-1 are positively related to increased carotid artery IMT in 
humans. (Larson et al, 2005)  
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Traditional risk factors 
 Age 
 Smoking 
 Hypertension 
 Hypercholesterolemia 
 Diabetes mellitus 
 Family history 
Novel cardiovascular disease risk factors 
 Cytokines (TNF-┙, IFN-┙, IL-6 and low IL-10) 
 Endothelial (sVCAM-1, VEGF, Ang-2, apoptosis of circulating angiogenic cells/ 
               endothelial progenitor cells and low annexin V binding) 
 Elevated C-reactive protein 
 Elevated homocysteine 
 Metabolic syndrome/insulin resistance 
Lupus-specific variables 
 Corticosteroids 
 SLE disease activity and SLE disease damage 
 Antiphospholipid antibodies 
 Anti-oxLDL antibodies, reduced antiphosphorylcholine antibodies 
 Proinflammatory HDLs 
 Lupus dyslipoproteinemia (high VLDL, high triglyceride, low HDL, high 
               lipoprotein A); decreased lipoprotein lipase activity 
 Renal disease 
Ang-2: Angiopoietin-2; HDL: High-density lipoprotein; oxLDL: Oxidized low-density 
lipoprotein; SLE: Systemic lupus erythematosus; sVCAM: Soluble vascular cellular 
adhesion molecule; VLDL: Very low-density lipoprotein. 
(Skamra & Ramsey-Goldman, 2010) 
Box 1. Risk factors for cardiovascular disease in systemic lupus erythematosus (Elliot JR, 
Mansi S, 2009. Copyright permission from Elsevier) 
8.2.2 Low-density lipoproteins and the development of foam cells 
Next, low-density lipoproteins (LDLs) are transported into artery walls, where they become 
trapped and bound in the extracellular matrix of the subendothelial space.(McMahon & 
Hahn, 2007) These trapped LDLs are then seeded with reactive oxygen species (ROS) 
produced by nearby artery wall cells, resulting in the formation of proinflammatory-
oxidized LDL . When endothelial cells are exposed to these proinflammatory OxLDL, they 
release cytokines such as MCP-1, M-CSF, and GRO, resulting in monocyte binding, 
chemotaxis, and differentiation into macrophages. (Nawab et al, 2000) 
The OxLDLs are phagocytized by infiltrating monocytes/ macrophages, which then become 
the foam cells around which atherosclerotic lesions are built. Elevated levels of circulating 
OxLDL are strongly associated with documented coronary artery disease in the general 
population.( Tsimikas et al, 2005) Elevated levels of circulating OxLDL have also been 
described in SLE patients, especially in those with a history of cardiovascular 
disease.(Frostegard et al, 2005) 
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Fig. 5. The interplay of LDL, HDL, and OxLDL with endothelial activation, monocyte 
migration, foam cell formation, and reverse cholesterol transport. (Macmohan  M, Hahn 
BV,2007.Copyright permission from Elsevier) 
Next, monocytes and T cells infiltrate the margin of the plaque formed by foam cells, and 
muscle cells from the media of the artery are stimulated to grow. These muscle cells 
encroach on the lumen of the vessel and ultimately lead to fibrosis, which renders the 
plaques brittle. The occlusion that results in MI can occur when one of these plaques 
ruptures, or when platelets aggregate in the narrowed area of the artery. (McMahon & 
Hahn, 2007) 
8.2.3 Normal HDL clears OxLDL from the endothelium: Abnormal proinflammatory 
HDL associate with accelerated atherosclerosis 
There are many mechanisms designed to clear OxLDL from the subendothelial space, 
including macrophage engulfment using scavenger receptors, and enhanced reverse 
cholesterol transport mediated by lipoprotein transporters in HDL. (McMahon & Hahn, 
2007) In addition to reverse cholesterol transport, HDL removes reactive oxygen species 
from LDL (via anti-oxidant enzymes in the HDL, such as paroxonase), thus preventing the 
formation of OxLDL and the subsequent recruitment of inflammatory mediators. (Nawab et 
al, 2000a, Nawab et al, 2004b) 
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Thus, although quantities of HDL partially determine atherosclerotic risk (low levels are 
associated with increased risk), HDL function is equally significant. (Barter et al, 2004) 
During the acute phase response HDL can be converted from their usual anti-inflammatory 
state to proinflammatory, and can actually cause increased oxidation of LDL. This acute 
phase response can also become chronic, and may be a mechanism for HDL dysfunction in 
SLE. It has been found that HDL function is abnormal in many women with SLE, 45% of 
women with SLE, compared to 20% of rheumatoid arthritis patients and 4% of controls, had 
proinflammatory HDL (piHDL) that was not only unable to prevent oxidation of LDL but 
caused increased levels of oxidation.(McMahon et al,2006a)McMahon et al reported  86% of 
patients with SLE who had plaque on carotid ultrasound had piHDL, compared to 39% who 
do not have plaque ( p < 0.0001). (McMahon et al, 2006b) This suggests that detecting piHDL 
may identify SLE patients at high risk for clinical atherosclerosis. The interplay of LDL, 
HDL, and OxLDL with endothelial activation, monocyte migration, foam cell formation, and 
reverse cholesterol transport is illustrated in Figure 9. 
8.3 Traditional risk factors 
Over the past 15 years, traditional CV risk factors have been described in patients with SLE. 
Patients from several large lupus cohorts have been reported to have a greater total number 
of Framingham study and other traditional risk factors, including hypertension, diabetes, 
dyslipidaemia, tobacco use and sedentary lifestyle than matched control subjects. (Asanuma 
et al, 2003) Others have discovered a greater occurrence of both insulin resistance and 
metabolic syndrome. The Toronto Lupus Cohort also reported that SLE patients with CV 
events have a greater total number of traditional CV risk factors than lupus patients without 
events. (Bruce et al, 2003) Premature menopause is commonly seen in lupus patients. 
Compared with age-matched controls, women with lupus are more likely to be post-
menopausal (38% vs. 19%) and reach menopause 4 years earlier. (Urowitz et al, 2007) These 
conventional risk factors of CVD are also associated with sub-clinical measures of 
atherosclerosis in SLE patients. Older age, hypertension, dyslipidaemia and diabetes are 
associated with the presence of carotid plaque. Finally, both hypertension and 
dyslipidaemia are independently predictive of CV events (MI and stroke) in SLE patients. 
(Elliott et al, 2008) 
8.4 Dyslipidaemia in SLE 
An atherogenic lipid profile has been described in SLE patients with elevated total 
cholesterol (TC), triglycerides (TG), low-density lipoprotein (LDL), very low-density 
lipoprotein (VLDL) and lipoprotein(a) [Lp(a)]  concentrations, as well as decreased high-
density lipoprotein (HDL) cholesterol levels. (Borba et al, 1994) Patients with lupus may also 
have altered HDL function. HDL cholesterol is normally an anti-inflammatory molecule that 
prevents the formation of oxidised LDL (ox-LDL) and foam cells that lead to plaque 
formation in the vasculature. A pro-inflammatory HDL (piHDL) is less able to prevent 
oxidation of LDL. piHDL was found in greater frequency in lupus patients with CVD than 
in those without known coronary disease. (Batuca et al, 2007)Additionally, paraoxonase 1 
(PON1) is an anti-oxidant component of HDL that inhibits oxidation of lipoproteins and 
breaks down ox-LDL. In SLE, PON1 activity is altered, and significant reductions of PON1 
are associated with both CV and cerebrovascular events. (Tripi et al, 2006)   One possible 
mechanism for the reduced PON activity seen in SLE may be due to auto-antibody 
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production. In a study by Batuca et al., patients with SLE were noted to have higher titres of 
antibodies to HDL and apolipoprotein A-1 (a lipoprotein associated with HDL) than healthy 
controls. (Batuca et al, 2007) PON activity was inversely correlated with the levels of 
antibodies to apolipoprotein A-1. 
8.5 Lupus-related risk factors 
Traditional risk factors alone do not fully explain the increased risk of CVD in lupus 
patients. Esdaile and colleagues reported a 10-fold relative risk of non-fatal MI and 17-fold 
relative risk of death from CHD, even after controlling for Framingham study risk factors. 
(Esdaile et al, 2001)These findings suggest that factors related to lupus itself, as well as its 
therapy, may be independent risk factors for CVD. 
8.5.1 Disease activity 
Ongoing inflammatory SLE disease activity is associated with CV risk. (Manzi et al 1997, 
Roman et al, 2003) A six-point increase in the Systemic Lupus Erythematosus Disease Activity 
Index (SLEDAI) score over 1 year correlated with a 5% increase in a 2-year CV risk. (Karp et al, 
2008) This same increase in SLEDAI score was associated with increases of 3.4 mmHg in 
systolic blood pressure, 1 mg/dl in glucose and 11.6 mg/dl in TG as well as a 2.3- mg/dl 
decrease in HDL cholesterol. In the study performed by Roman and colleagues, the diagnosis 
of SLE itself, a longer duration of disease and greater disease damage (measured by SLICC-
Damage Index [SLICC-DI]) were independent predictors of carotid plaque. (Roman et al, 2003) 
Similarly, Manzi et al. demonstrated that duration of lupus and disease damage (measured by 
SLICC-DI) were significantly associated with a higher carotid plaque index.(Manzi et al, 1999) 
8.5.2 Renal disease 
Renal disease is one of the most common internal organ manifestations of SLE. Both 
hypertension and dyslipidaemia are well described with lupus nephritis and renal disease. 
Lupus renal disease is also associated with increased atherosclerosis. In fact, nearly 50% of 
deaths in lupus patients with renal disease are attributed to CV or cerebrovascular disease. 
(Appel et al, 1994) 
8.5.3 Autoantibody production 
Systemic lupus erythematosus is characterized by autoantibody production. The immune 
reactions involving antibody production modulate atherosclerosis. Antiphospholipid 
antibodies and anti-oxLDL have been associated with CAD mortality in the general 
population. However, the relationship is nonlinear, making antibody status difficult to use 
as a predictor of individual risk. (Erkkila et al, 2005) Patients with SLE and secondary 
antiphospholipid antibody syndrome (APS) had a higher prevalence of carotid plaque than 
patients with primary APS. (Jimenez et al, 2005) In patients with SLE, the prevalence of 
anticardiolipin antibodies is quoted between 24 and 39% and for lupus anticoagulant it is 
quoted as 15–30%. However, only 50% of patients with the antiphospholipid antibodies will 
have a clinical event (defined as arterial or venous thrombosis or pregnancy morbidity), and 
thus have APS. (Giles & Rahman, 2009) A retrospective analysis carried out by Bessant et al. 
demonstrated that patients with SLE just prior to a CVD event (MI, angina, cerebrovascular 
accident [CVA] or peripheral vascular disease) were more likely to have the presence of 
lupus anticoagulant compared with patients with SLE without CVD, after controlling for 
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disease duration.(Bassant et al,2006) Anti-┚-2-glycoprotein I antibody has also been 
associated with increased risk of acute coronary syndrome in the general population.( Veres 
et al, 2004). Anti ┚-2-glycoprotein I antibodies was identified as a significant risk factor for 
arteriosclerosis obliterans in SLE patients, and was associated strongly with ischemic heart 
disease in patients with SLE. (Cederholm et al, 2005) 
Annexin V plays a role in atherosclerotic lesions since it is believed to form a protective 
shield over thrombogenic cell surface proteins.(Fig.10) Decreased annexin V binding to the 
endothelium, caused by anticardiolipin IgG, was found in the sera of patients with SLE and 
CVD. (Cederholm et al, 2005) 
In addition, antibodies against oxLDL have been found in patients with angiographic 
CAD. The oxidation of LDL may lead to the formation of neoepitopes that bind to 
scavenger receptors of macrophages and lead to uptake of oxLDL, accelerating foam cell 
formation in the atherosclerotic plaque. The level of oxLDL was associated with arterial 
disease (defined as clinically evident MI, angina, peripheral claudication or thrombosis). 
(Frostegard et al, 2005) 
In patients with an established history of hypertension, high levels of IgM 
antiphosphorylcholine (anti-PC) antibodies were shown to be atheroprotective; they resulted 
in less progression of IMT on carotid ultrasound (OR: 0.46; 95% CI: 0.25–0.85; p = 0.01) . (Su j et 
al, 2006) Decreased levels of anti-PC antibodies were observed in both SLE cases with CVD 
and SLE controls without CVD compared with population controls. (Skamra & Ramsey-
Golman, 2010) 
 
 
aPL interfere with binding to endothelium of antithrombotic Annexin  
V. Frostegard J,J Int Med,2005;257(6)485-495.Copyright permission from John Wiley & Sons. 
Fig. 6. Potential mechanism of atherothrombosis in systemic lupus erythematosus (SLE). 
8.5.4 SLE therapy 
Corticosteroids: 
Corticosteroid therapy in SLE patients is often a double-edged sword. While it is still one of 
the most effective therapies for managing lupus disease activity, it has numerous metabolic 
side effects on blood pressure, blood glucose, lipids andweight. Petri et al. reported that a 
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change of 10 mg of prednisone leads to an increase of 7.5mg/dl of TC, a 1.1-mmHg increase 
in mean arterial blood pressure and a 2.5-kg weight gain. (Petri et al, 1994) Additionally, 
longer duration of corticosteroid therapy is associated with sub-clinical CVD (Manzi et al, 
1999) and independently predicts CV events in lupus patients. (Elliott et al, 2008) Lupus 
patients on corticosteroids are also likely to have greater inflammatory disease burden, 
placing them at higher CVD risk. MacGregor et al. found a corticosteroid dose-related effect. 
Above a daily dose of 10 mg of prednisolone, the triglyceride (TG) and Apo B levels were 
elevated compared with controls without SLE, but below a daily dose of 10 mg prednisolone 
there was no difference between controls and SLE patients. (Macgregor et al, 1992) Similarly, 
Petri et al. found that prednisone of over 10 mg daily was associated with 
hypercholesterolemia, defined as total cholesterol of more than 200 mg/dl. (Petri, 2000) 
Additionally, Montreal Lupus Clinic researchers reported that SLE patients on 30 mg of 
corticosteroids have a 60% greater 2-year CV risk than do SLE patients with the same 
disease activity and traditional risk factors but not on corticosteroids. This finding 
emphasizes the need for corticosteroid monitoring and the use of steroid-sparing agents in 
the clinical care of SLE patients. (Thompson et al,2008) Patients with SLE and CVD were 
more likely than SLE age-matched controls (without CVD) to have taken a mean dosage of 
prednisone of over 7.5 mg/day (p = 0.04) and more likely to have been treated with pulse 
methylprednisolone (p = 0.03) (Bessant et al, 2006) A longer duration of corticosteroid use 
(11 vs 7 years; p = 0.002) was more common in the patients who had an event than in those 
without an event. (Manzi etal, 1997) Women with SLE who had a longer duration of 
prednisone use and higher cumulative dose of prednisone are more likely to have carotid 
plaque on ultrasound ( Manzi et al,1999) and the IMT progression is associated with years of 
steroid use.(Thompson et al,2008) 
Anti-malarial medication: 
Hydroxychloroquine (HCQ) therapy has been shown to have several beneficial CV effects 
in SLE patients. HCQ use in SLE patients has been shown to reduce TC, LDL and TG 
levels. (Wallace et al, 1990)The lipid lowering effect of HCQ is greatest in younger 
patients (age 16–39 years) and may offset the dyslipidaemia associated with corticosteroid 
therapy. (Rahman et al, 1999) Lupus patients taking HCQ have had significantly lower 
mean glucose levels and markers of insulin resistance. (Petri, 1996) HCQ has been 
postulated to prevent future thrombotic events, (Erkan et al, 2002) and lupus patients on 
HCQ therapy are less likely than those not on it to have carotid plaque. Its protective 
effect on the vasculature may be in part due to inhibition of aPL-mediated platelet 
activation. (Roman et al, 2003) 
Immunosuppressant medications: 
Roman's study demonstrated that patients with carotid plaque by B-mode ultrasound 
were less likely to have been treated with prednisone and cyclophosphamide when 
analyzed by multivariate analysis. (Roman et al, 2003) Mycophenolate mofetil (MMF) has 
been studied in patients with renal and cardiac transplants and found to reduce allograft 
vasculopathy and intimal thickening compared with those treated with azathioprine, as 
reviewed by Gibson and Hayden.(Gibson & Hayden, 2007). While there are no specific 
studies regarding cardiovascular outcomes in patients with SLE who take MMF, 
extrapolating the transplant data suggests this may be a useful choice for treating LN. 
Immunosuppressant medications should be used judiciously and corticosteroid dosage 
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should be minimized, but control of SLE should not be sacrificed to avoid CVD risk. 
(Skamra &Ramsay-Goldman, 2010) 
Estrogens & hormone replacement therapy 
Patients with antiphospholipid antibodies are at increased risk of thrombosis. Thus, general 
recommendations include discontinuing estrogen usage, despite a lack of randomized, 
controlled trials.(Sammaritano, 2007) A prospective study evaluating patients with SLE who 
took hormone replacement therapy (HRT) revealed that HRT was not a risk factor for CAD, 
despite the presence of antiphospholipid antibodies in 74.6% of HRT users.(Hochman et al, 
2009) However, the role of hormones in patients with SLE who lack antiphospholipid 
antibodies has been more clearly defined. Both the Safety of Estrogens in Lupus 
Erythematosus National Assessment (SELENA) study and the LUMINA study found that 
exogenous hormones were safe to use in their patient populations as long as SLE was stable, 
and did not increase the risk of arterial thrombosis in lower risk patients. ( Fernandez et al, 
2007) Based on risk and needs, oral contraceptive and HRT use are recommended in 
properly selected patients who do not have antiphospholipid antibodies.(Skamra &Ramsay-
Goldman, 2010) 
8.5.5 Endothelial dysfunction 
Many soluble markers of endothelial dysfunction have been studied in atherosclerosis, 
including cytokines, chemokines, soluble adhesion molecules and acute phase reactants. 
Their clinical use is limited by their instability, inadequate laboratory performance and lack 
of standardization at this time; however, they may prove to be a valuable tool in the future. 
Biochemical markers of endothelial cell activation, such as soluble thrombomodulin, von 
Willebrand factor and tissue plasminogen activator, are increased in patients with SLE. 
(Constans et al, 2003) While soluble vascular cellular adhesion molecule (sVCAM)-1 was 
elevated only in the patients with SLE and CVD. This is of further interest, since sVCAM-1 is 
associated with systemic TNF-┙. There is positive correlation between TNF-┙ and plasma 
TGs, VLDL TGs and VLDL-C]. SLE patients with a higher IMT value using B-mode 
ultrasound had significantly higher mean plasma VEGF levels compared with controls after 
adjusting for age, smoking and other Framingham risk factors. (Svenungsson et al, 2003) 
Thus, these soluble biomarkers may have a future role in identifying SLE patients at risk for 
CVD.The Tie-2 receptor (a vascular-specific tyrosine kinase receptor), through its interaction 
with angiopoietin (Ang)-1, maintains vessel integrity, inhibits vascular leakage, suppresses 
inflammatory gene expression, and prevents recruitment and transmigration of leukocytes. 
Ang-2 has emerged as a key mediator of endothelial cell activation and facilitates 
endothelial cell inflammation by counterbalancing the effects of Ang-1 and disrupting these 
functions. (Skamra &Ramsay-Goldman, 2010) Ang-2 concentrations were elevated in 
hypertensive patients compared with healthy controls (4.23 ± 3.1 vs 0.88 ± 0.43 ng/ml;  
p < 0.0001); and it was particularly elevated in those patients with atherosclerosis (p = 0.02). 
Furthermore, Ang-2 concentrations correlated with other vascular markers of endothelial 
cell activation, including VCAM-1 and ICAM-1. Mean serum Ang-2 concentrations were 
markedly elevated in patients with active SLE compared with inactive SLE (8.6 vs 1.4 
ng/ml; p = 0.010) and healthy controls (8.6 vs 1.1 ng/ml; p < 0.001), and Ang-2 remained 
significantly elevated in patients with inactive SLE compared with healthy controls. (Skamra 
&Ramsay-Goldman, 2010) Maintaining vascular integrity after damage is a role played by 
www.intechopen.com
 
Systemic Lupus Erythematosus 
 
294 
endothelial progenitor cells (EPCs) and myelomonocytic circulating angiogenic cells. 
Decreased levels or abnormal function of those cells is an established atherosclerotic risk 
factor. (Hill et al, 2003) SLE patients possess significantly fewer numbers of circulating EPCs 
as well as impaired differentiation of EPCs and circulating angiogenic cells into mature 
endothelial cells that are capable of producing VEGF. These abnormalities are triggered by 
IFN-┙, which induces EPC and circulating angiogenic cell apoptosis. SLE EPCs/circulating 
angiogenic cells have increased IFN-┙ expression, which might promote accelerated 
atherosclerosis. (Hill et al, 2003) 
8.5.6 Cytokines 
In addition to the relationship between TNF-┙ and IFN-┙, other cytokines and their 
associated polymorphisms (IL-10 and IL-6) have also been implicated in the relationship 
between CVD and SLE. IL-10 has an atheroprotective role compared with TNF-┙, which is 
atherogenic. Both IL-10 and TNF-┙ are seen increased in SLE patients with CVD compared 
with SLE patients without CVD or controls. IL-6 overproduction has been associated with 
SLE, CVD and C-reactive protein (CRP) elevations. Measurement of individual cytokines is 
laborious and may be difficult to interpret without an overall cytokine profile. The role of 
IL-10 and IL-6 and many other cytokines in SLE and CVD remains to be fully elucidated. 
(Skamra &Ramsay-Goldman, 2010) 
8.5.7 CRP 
In addition to its relationship with arterial stiffness, an elevated level of serum CRP has been 
associated with MI and stroke in the general population. Its role in risk stratification remains 
unclear because it might improve risk prediction beyond the traditional Framingham 
calculation; however, further study will be required before it can be accepted as a standard 
CVD risk factor. (Lloyd-Jones et al, 2006) In patients with SLE, an elevated serum CRP has 
been associated with the presence of carotid plaque. Elevated CRP has also been associated 
with the highest quartile of IMT on carotid ultrasound in SLE patients. (Manzi et al, 1999) 
CRP is also found to have association with cardiovascular events and SLE disease activity as 
measured by the Systemic Lupus Activity Measure, but not with overall damage accrual as 
measured by the SLICC-DI. (Szalai et al, 2005; Bertoli et al, 2008) 
8.5.8 Homocysteine 
Homocysteine is believed to be a toxin that results in endothelial injury and dysfunction in 
patients with CVD, but its exact role remains to be defined. Homocysteine may have a role 
in differentiating between patients with SLE and CVD and those with CVD without SLE. 
Patients with SLE from the Toronto Lupus Cohort had higher mean homocysteine levels 
compared with age-matched controls, despite having higher folate levels. Studies found that 
a homocysteine level above 14.1 mmol/l was an independent risk factor for development of 
CAD in patients with SLE after controlling for established risk factors (Svenungsson et al, 
2001, Petri, 2009) Homocysteine concentration was found to be significantly higher among 
patients with progressive plaque compared with patients without carotid plaque. (Roman et 
al, 2007) In addition to SLE, renal failure is a known cause of hyperhomocysteinemia. While 
the role of homocysteine is not completely defined, Von Feldt suggests that it may be a 
useful initial test in the evaluation of SLE patients in order to determine the presence and 
extent of subclinical atherosclerotic disease. (Von Feldt et al, 2008) 
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8.6 Assessment and management  
8.6.1 Assessment and management of traditional risk factors (table 1.) 
Obesity 
Assessment 
The National Heart, Lung, and Blood Institute (NHLBI), (National Institute of Health,1998) 
American Heart Association (AHA) (Smith et al, 2006)  and the American College of 
Cardiology (ACC) recommends checking weight and height to calculate BMI, as well as 
waist circumference, at each visit. Waist circumference is a marker of visceral or intra-
abdominal fat and should be assessed at the iliac crest. Goal BMI is recommended from 18.5 
to 24.6 kg/m2 and waist circumference should be <40 inches in men and <36 inches in 
women. (Smith et al, 2006)    
Management 
Preventing obesity is the first line of defense. Physicians should educate patients to avoid 
weight gain by promoting healthy eating and physical activity. Specific to lupus itself, 
aggressive control of joint and fatigue symptoms and global lupus disease activity could 
help facilitate physical exercise. As corticosteroid use can lead to weight gain and other 
metabolic risks, minimizing the corticosteroid dose by adding a steroid-sparing agent, such 
as HCQ, or an immunosuppressive agent may be needed. For those patients with a BMI >25 
kg/m2 or whose waist circumference is >40 inches in men or >35 inches in women, a 
combined dietary and physical exercise programs is indicated. These dietary and exercise 
recommendations can also be applied to patients with dyslipidaemia, hypertension and 
diabetes (see below). 
Diet: AHA Diet and Lifestyle recommendations (Lichtenstein et al, 2006) advocate the 
following: a diet rich in fruits, vegetables and whole-grain, high-fiber foods, consuming fish 
(specifically oily fish) twice a week, limiting saturated fat to <7% (trans fat to <1%) and 
cholesterol to <300 mg /day by choosing lean meats and fat-free or low-fat dairy products, 
minimizing beverages and foods with added sugars, low or no salt diet and consuming 
alcohol in moderation. 
Consultation with a nutritionist or dietitian is strongly encouraged. An individualized 
dietary plan, taking into account specific health concerns and medications, will be a 
powerful tool for lupus patients and their CV health. (Elliott &Manzi, 2009) 
Exercise. Physicians should take every office visit as an opportunity to encourage patients to 
exercise. The AHA recommends 30 min of moderate-intensity (brisk walking) aerobic 
activity 5 days per week or 20 min of vigorous-intensity (jogging) 3 days a week for healthy 
adults. Haskell et al, 2007) Resistance training (weight lifting) to improve muscle strength 
and endurance is advocated twice per week and should include all 10 major muscle groups. 
Patients should be encouraged to increase their daily lifestyle activities, such as walking to 
the store and using stairs instead of elevators. For those with cardiac history or recent 
vascular surgery, physicians should provide a medically supervised exercise program. 
(Smith et al, 2006)    
In addition to CV benefits, physical exercise may improve conditions related specifically to 
SLE disease. SLE patients can improve their aerobic capacity and exercise tolerance and 
fatigue after following an exercise program, without aggravating their SLE disease. (Clarke-
Jenssen et al, 2005) Aerobic exercise can also improve quality of life in patients with SLE by 
improving both depression levels and global sense of well-being. (Avan & Martin, 2007)  
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Risk factors Monitoring strategies Management strategies 
Obesity Check weight, height, and waist 
circumference at each visit 
Goal BMI <25 kg/m2 
Goal waist circumference <35 inches for 
women or <40 inches for men 
 
 
Regular exercise 
Dietary counseling 
Referral to nutritionist and exercise 
therapist 
Referral to hospital- or community-
based weight loss programs 
Lowest possible dose of 
corticosteroids 
Dyslipidemia Check fasting lipid panel at initial visit, 
then yearly 
If dyslipidemic, check lipids every 6 
months 
or 6 weeks after medication changes 
Goal LDL <100 mg/dl 
Goal LDL <70 mg/dl for those with 
known CVD or PVD or diabetes 
 
Encourage lifestyle modification 
with diet, exercise, and weight loss 
counseling 
Lowest possible dose of 
corticosteroids 
Consider hydroxychloroquine 
therapy 
Consider lipid lowering therapy for 
those not at LDL goal 
Consider ASA therapy 
Consider preventive cardiology 
evaluation 
Hypertension Check blood pressure at each visit and 
between visits 
for those on corticosteroids or NSAIDs 
Goal BP <130/80 mmHg 
 
Aggressive blood pressure control 
Encourage lifestyle modification 
with diet, exercise, and weight loss 
counseling 
Addition of ACE inhibitor for those 
with diabetes or renal disease 
Lowest possible dose of 
corticosteroids 
Consider ASA therapy 
 
Diabetes 
Mellitus/Insulin 
Resistance 
 
Check fasting glucose yearly 
Consider checking fasting insulin and 
calculate 
insulin resistance 
Oral glucose tolerance test if needed. 
Goal fasting glucose <126 mg/dl 
Goal HbA1c <7% 
 
Endocrinology evaluation 
Early aggressive therapy to maintain 
HbA1c<7% 
Encourage lifestyle modification 
with diet,exercise, and weight loss 
counseling 
Consider hydroxychloroquine 
therapy 
Consider ASA therapy 
Aggressive management of blood 
pressure, lipids, and other CV risk 
factors 
 
Tobacco Use Ask patient about tobacco use at each 
visit 
Goal of complete tobacco cessation 
 
 
 
Discuss importance of tobacco 
cessation 
Assess willingness to quit 
Referral to tobacco cessation 
program 
Suggest pharmacotherapy 
Consider ASA therapy 
BMI: body mass index. LDL: low-density lipoprotein. HDL: high-density lipoprotein. CVD: 
cardiovascular disease. PVD:peripheral vascular disease. BP: blood pressure. NSAIDs: nonsteroidal 
anti-inflammatory drugs. HbA1c: glycosylated hemoglobin.ASA: aspirin. 
Table 1. Assessment and Management strategies of traditional risk factors in patients with 
SLE. (Elliot JR, Mansi S, 2009. Copyright permission from Elsevier) 
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Given these data, physicians should consider referring patients to an exercise physiologist 
or specialists in physical exercise. An individualized exercise plan that takes into account 
patients specific needs and limitations may help to assure their long-term commitment to 
being physically fit. (Elliott &Manzi, 2009) 
Dyslipidaemia: 
Assessment At baseline and yearly, a fasting lipid panel (TC, LDL, HDL and TG levels) 
should be performed on patients with SLE. It is proposed that lupus patients be considered 
CHD risk equivalents, similar to patients with diabetes. Accordingly, based on the National 
Cholesterol Education Program Adult Treatment Panel (ATP III), (National Cholesterol 
Education Program [NCEP], 2001) the goal cholesterol levels in lupus patients should be: TC 
<200 mg/dl, LDL <100 mg/dl, TG <150 mg/dl and HDL >40 mg/dl. 
Management 
Lifestyle modifications should be considered as first-line approach, with an emphasis on 
reducing saturated and transunsaturated fat and cholesterol intake and weight loss. The 
American Diabetes Association (ADA) and the ACC issued a consensus statement 
recommending both lifestyle modifications and lipid pharmacological therapy, regardless of 
LDL level, for all patients with known CVD or for high-risk groups, such as patients with 
diabetes .(Brunzell et al, 2008) They further recommended a tighter LDL goal of <70 mg/dl. 
There is a scarcity of lipid-lowering therapy clinical trials in SLE. Petri et al. reported an 
improvement in carotid IMT in SLE patients treated with atorvastatin.(Petri et al, 2006) Most 
do not advocate the wide-spread use of statins in all SLE patients, (Toloza et al, 2007 but 
reserve its use for those with established vascular disease or diabetes. 
Based on the available literature, Elliott & Manzi propose the following management of 
dyslipidaemia in SLE patients: 
- Regardless of LDL level, corticosteroid therapy should be minimized, HCQ be 
considered and lifestyle modifications be initiated.  
- LDL goal of <100 mg/dl or <70 mg/dl for those with sub-clinical CVD, known CV or 
peripheral vascular disease (PVD), or diabetes 
- Consideration of lipid-lowering therapy for LDL >100 mg/dl or >70 mg/dl for those 
with subclinical CVD, known CVD or PVD, or diabetes 
Hypertension 
Assessment 
The Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High 
Blood Pressure (JNC 7) continues to define hypertension as exceeding 140/90 mmHg. 
(Chobanian et al, 2003) However, the report recommends for the first time, a more stringent 
goal of <130/80 mmHg for patients with high-risk conditions, such as diabetes or chronic 
kidney disease. Based on this literature, Elliott & Manzi recommended a goal blood pressure 
of <130/80 mmHg for patients with SLE. Additionally, a blood pressure reading should be 
obtained at each physician visit and between visits for lupus patients on corticosteroids and 
non-steroidal anti-inflammatory drugs. 
Management 
Lifestyle modifications regarding diet, specifically salt restriction, exercise, weight control 
and alcohol moderation, is recommended for all patients with a blood pressure >140/90 
mmHg. Except for those with known ischaemic heart disease or diabetes, lowering of blood 
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pressure is more important than the choice of anti-hypertensive agent. Anti-hypertensive 
therapy should also be initiated when blood pressure readings are >140/90 mmHg. 
Aggressive combination therapy is often needed to obtain blood pressure goals, and the JNC 
7 recommends starting combination therapy when SBP >150 mmHg or DBP >90 
mmHg.(Chobanian et al, 2003) Angiotensin-converting enzyme (ACE) inhibitors, 
angiotensin receptor blockers (ARBs), calcium channel blockers or thiazide diuretics are 
typically first-line therapy for hypertension. However, a beta-blocker should be used in 
patients with known CAD and an ACE or ARB is recommended in those with diabetes or 
renal disease. Corticosteroid therapy should also continue to be minimized given its 
relationship with blood pressure elevation. (Elliott & Manzi, 2009) 
Diabetes mellitus 
Assessment 
All lupus patients should have a fasting glucose checked yearly. The American Diabetic 
Association (ADA) defines diabetes with either a fasting plasma glucose of >126 mg/dl or a 
glucose tolerance test of >200 mg dl. (Nathan et al, 2006) Goals of therapy should be near-
normal glucose levels and a haemoglobin A1C level of <7%. 
Management 
Lupus patients with diabetes should undergo structured diabetic education programs that 
emphasize aggressive lifestyle changes in diet, exercise and weight management. The ADA 
also recommends metformin therapy in addition to lifestyle changes for all patients newly 
diagnosed with diabetes. (Nathan et al, 2006)  If this regimen is not effective in reaching 
glucose or haemoglobin A1C goals, then another oral diabetic agent or insulin should be 
started. Endocrinology referral should be strongly encouraged for these patients. 
Other risk factors: Other CV risk factors must also be evaluated and aggressively treated. As 
described above, blood pressure therapy is recommended at >140/90 mmHg and statin 
therapy at LDL >100 mg /dl. All patients should be counseled on tobacco cessation and 
considered for aspirin therapy.HCQ should also be considered for all lupus patients with 
impaired glucose function and diabetes. Similarly, corticosteroid therapy should be 
minimized to avoid exacerbations of hyperglycaemia. 
8.6.2 SLE-specific and inflammatory risk factor assessment and management 
A summary of the assessment and management strategies for lupus-specific and 
inflammatory CV risk factors is outlined in Table 2. 
8.7 Conclusion 
Cardiovascular involvement in SLE may easily be overlooked until a full blown cardiac 
dysfunction or complication occurs. 
 Cardiac involvement  in SLE involves all the three layers of the heart (pericardium, 
myocardium, endocardium) 
 Pericarditis is a common cardiac manifestation of SLE and can present rarely with 
cardiac tamponade being the initial presentation. Diagnosis is based on ECG and 
echocardiography findings. Pericarditis responds well to steroid therapy, and rarely 
may progress to cardiac tamponade necessitating pericardiocentesis.Refractory cases 
may require pericardial window. 
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Risk factors Monitoring strategies Management strategies 
SLE Disease activity 
 
 
Assess disease activity 
and medications at each visit 
 
Lowest possible dose of 
corticosteroids 
Add steroid sparing agent if 
unable to lower corticosteroid 
dose 
Consider hydroxychloroquine 
therapy 
Consider ASA therap 
SLE Renal disease Assess renal parameters at each 
visit: BP, serum albumin, 
creatinineو 
and urinalysis 
Goal BP <130/80 mmHg 
Goal to normalize creatinine and 
albumin 
Goal proteinuria <300 mg/dl 
Aggressive blood pressure 
control 
Addition of ACE inhibitor 
Consider ASA therapy 
 
Antiphospholipids 
 or Lupus 
Anticoagulant positivity 
Check antiphospholipids, Lupus 
Anticoagulant, and beta 2 
glycoprotein antibody status 
initially and as needed 
Consider hydroxychloroquine 
therapy 
Consider ASA therapy 
Inflammatory CV risk 
factors In SLE 
C-reactive protein 
 
Homocysteine 
 
 
 
 
 
Consider checking as an additive 
predictive factor 
Check initially and as needed 
 
 
 
 
Unclear at this time 
 
Unclear at this time, but consider 
folic acid supplementation for 
hyperhomocysteinemia 
Table 2. Summary of SLE-specific CV risk factors in patients with SLE (Elliot JR, Mansi S, 
2009. Copyright permission from Elsevier) 
 Myocarditis presents in 3-15% of the SLE patients clinically,but a common finding in 
autopsy studies. It may present with florid heart failure or subacutely as tachycardia 
and dyspnea.Myocarditis should be considered in patient with tachycardia and fever, 
with a 3rd heart sound with abnormal ECG in those with a new murmurs or conduction 
disturbances and those with congestive heart failure.Treatment is with high dose 
steroid and with IV cyclophosphamide in refractory cases in addition to antifailure 
therapy.Anticoagugation should be considered in those with cardiomyopathy. 
 Valvular heart disease due to Libman Sacks endocarditis is found less frequently in the 
era of corticosteroids.The mitral valve is the most common valve involved followed by 
the the aortic valve.Echocardiography is the modality of choice for diagnosis.Use of 
steroids to shinken the vegetation is controversial and as may led to fibrosis. Bacterial 
prophylaxis is indicated in patients with significant regurtitation with jet lesions even in 
the absence of nodules. 
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 Arrhythmia and conduction defects occour in 10% of the patients with SLE either as a 
consequence of pericarditis or myocarditis or involment of the conduction system by 
fibrosis or atherosclerosis. AntiSSA/RO associated cardiac manifestations include 
transient fetal heart block, QTc prolongation, sinus bradycardis, late on-set 
cardiomyopathy, endocardial fibroelastosis and cardiac malformations.In the adult 
heart may cause QTc prolongation in lupus patients. 
 Coronary arteritis presents with angina or myocardial infarction in a child or a young 
adult who do not have a long history of corticosteroid therapy.Serial coronary 
angiography is the proposed diagnostic modality.Corticosteroids may have rapid relief 
of the angina and may need cyclophosphamide. 
 Premature atherosclerosis, cardiovascular risk factors and cardiovascular events all 
occur at a younger age in patients with SLE compared with the general population. 
 After controlling for traditional Framingham risk factors, patients with SLE still have a 
7.5-fold (95% CI: 5.1–10.4) excess risk of overall coronary heart disease.This suggests 
that SLE itself carries an independent risk for CVD and exposes the failure of the 
Framingham risk calculator to capture a younger at-risk population. 
 Traditional risk factors, lupus related, and novel inflammatory CV risk factors are 
implicated in the pathogenesis of premature atherosclerosis. 
 Treatment recommendations for patients with SLE are based on other high-risk 
populations since there are no randomized, controlled trials that demonstrate the 
efficacy of interventions on cardiovascular events in SLE. 
 Lifestyle modifications and/or statins should be used to lower LDL-cholesterol below 
100 mg/dl as suggested in the National Cholesterol Education Program (NCEP) Adult 
Treatment Panel III guidelines. 
 Hypertension should be treated to maintain a blood pressure less than 130/80 mmHg. 
First-choice medication for patients with SLE should probably be angiotensin-
converting enzyme inhibitors (or angiotensin receptor blockers), especially in patients 
with concomitant lupus nephritis or diabetes mellitus.  
 Low-dose daily aspirin therapy is recommended in patients with SLE barring an 
absolute contraindication. 
 Use of antimalarial medications in all patients with SLE is recommended. 
 Use of corticosteroids should be minimized and immunosuppressant medications 
should be used judiciously, but control of SLE should not be sacrificed to minimize 
CVD risk. 
 Smoking cessation, regular aerobic exercise and maintaining a normal BMI are 
recommended in all patients with SLE. 
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